Stocksigma LogoStocksigma Logo

Piramal Pharma to Acquire Balance 26% Stake in Subsidiary Yapan Bio

Piramal Pharma's Administrative Committee approved exercising its call option to acquire the remaining 26% equity stake in subsidiary Yapan Bio Private

Piramal Pharma to Acquire Balance 26% Stake in Subsidiary Yapan Bio

Piramal Pharma Ltd 路 Others (Uncategorized) 路 18 Nov 2026, 10:31 pm

Piramal Pharma to Acquire Balance 26% Stake in Subsidiary Yapan Bio Piramal Pharma's Administrative Committee approved exercising its call option to acquire the remaining 26% equity stake in subsidiary Yapan Bio Private Limited from existing shareholders. Following completion of the transaction, Piramal Pharma's shareholding in Yapan will increase from 74% to 100%, making it a wholly owned subsidiary. Yapan operates as a CDMO specializing in process development, characterization, and Phase I/II GMP manufacturing for vaccines and biologics. Final terms, including acquisition consideration and effective transfer date, remain subject to finalization and definitive documentation.

Original exchange filing (PDF)

More announcements from Piramal Pharma Ltd

All Piramal Pharma Ltd announcements